Morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Incorporated's Second Quarter 2025 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ray Nash, Corporate Finance Leader for Novanta. Please go ahead. Thank you very much. Good morning and welcome to Novanta's Second Quarter 2025 Earnings Conference Call. This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra, and our Chief Financial Officer, Robert Buckley. If you have not received a copy of our earnings press release issued today, you may obtain it from the Investor Relations section of our website at www.novanta.com. Please note this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued earlier today, and also those in our SEC filings. We may make some comments today, both in our prepared remarks and in our responses to questions that may include forward-looking statements. These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. You should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release. To the extent that we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the Investor Relations section of our website after this call. I'm now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra. Thank you, Ray. Good morning, everybody, and thanks for joining our call. Novanta delivered solid second quarter results, meeting or exceeding expectations for sales, margins, and profit. Revenue reached $241 million, which represents reported revenue growth of 2% and organic revenue declines of 2%, surpassing guidance. New product revenue grew by over 50% year-over-year. Customer orders grew 10% year-over-year and 20% sequentially, reflecting a strengthening outlook. We also saw significant design win activity growing more than 150% year-over-year. Adjusted gross margins held at 46% and adjusted EBITDA margin was 22%, both in line with expectations. These results reflect the strength of Novanta's business model, team, and culture, and the power of using the Novanta Growth System to optimize company performance in a very fluid macroeconomic and trade environment. I'm proud of the team's strong execution of our tariff response strategy. Our long-term growth strategy remains focused on winning in markets with long-term secular tailwinds, such as precision and AI-driven robotics and automation, advancement of the invasive and robotic surgery, and precision medicine. We built trusted long-term collaborative partnerships with the world's leading OEM customers by solving their most challenging needs with our proprietary technology solutions, securing up to 10 years of exclusive and sticky designing platforms. While our products typically represent no more than 10% of our customers' bill of material, they enable differentiation and innovation in their systems for their customers in terms of clinical outcome, throughput, yield, cost per procedure or part, or never before possible performance. In the last decade, our portfolio has evolved significantly. We've expanded into healthcare growth markets, which are now approximately 55% of our business. We have increased our recurring consumables revenue to approximately 15% of sales. We have increased our revenue from intelligent subsystems with embedded software to approximately 30% of sales, which is margin accretive for Novanta. We intend to continue to expand our portfolio into these areas. Now, let me provide an update on the customer demand and market dynamics that we're seeing. Our sales to medical device markets remain exceptionally strong, with patient procedure growth rates, hospital spending, and our share gains driving sustained double-digit growth in our advanced surgery business in the second quarter and year to date. Our new product launches in surgical robotics and minimally invasive surgery applications are ramping very successfully. These products are designed to significantly enhance patient safety, improve surgical throughput, and help meet new regulatory requirements as U.S. states and countries around the world pass legislation regarding surgical smoke evacuation. Novanta is on track to reach $50 million of incremental new product revenue for 2025, mainly due to the strong outlook for the next-generation medical devices. Rapid adoption of these products supports our confidence that the advanced surgery business revenue will nearly double by 2030, up from $200 million in 2024. Medical consumables, a strategic focus for Novanta, are expected to account for approximately 15% of sales in 2025, with ongoing double-digit growth rates. Our success stems from long-term innovation investment and strong customer relationships, and we believe we now have the expertise and scale to expand into adjacent recurring medical consumables segments. We're also very excited to announce two major design wins in the second quarter in the minimally invasive surgery market. First, we won a new product program with one of the largest medical OEM customers to develop a third-generation insufflator device and consumables, which will be launched in the next few years. This design win shows our strong long-term partnership with leading OEMs and our ability to provide leading-edge innovations over multiple generations of our products. Second, with a separate medical OEM customer, we won a contract to develop a next-generation pump for their upcoming endoscopy tower. Our product will provide multifunctional pump capabilities, along with proprietary sensing and seamless integration with other devices on the customer's towers. This represents our second major win of next-generation pumps, with more in progress. Moving on, our robotics and automation applications continue to see strong demand despite the global trade disruptions, as evidenced by the strong double-digit revenue growth in the second quarter. Growth in this business is driven by demand for a product that supports physical AI applications, such as warehouse automation, precision robotics, and humanoids. We expect sales into these applications to double in 2026 versus 2025, and then to double again in 2027. We believe these physical AI applications represent an incremental $1 billion addressable market for Novanta by 2030. To that point, we're excited to announce a significant contract signed in July with a leading e-commerce and warehouse robotics company. This represents a $50 million revenue opportunity over the next three years. Because of the timing, this design win will be included in our third quarter metrics, and revenue will start in 2026. Taking a step back, the warehouse automation space is booming because of AI, labor shortages, and latest advancements in physical AI sensor technologies. As a result, leading OEM players are aggressively deploying high-conviction use cases. Novanta's proprietary technology offers precise touch and safe movement for robots, enabling smarter, faster, and more efficient goods handling, critical capabilities for more modern warehouse operations. I'm also pleased to share progress in humanoid robotics. This emerging field is in early development, and we're collaborating with over 10 leading humanoid players across North America and Europe. We're working with these players on multiple slots with significant content. We hope to announce specific design wins in the future as this market matures and these players finalize their product architectures. The same unique Novanta sensing and servo drive capabilities that are used in warehouse automation and surgical robotics are also relevant in humanoids, so we have a competitive advantage with platform technologies relevant for multiple physical AI robotics applications. This advantage has been built up over years with our growth playbook: consistent investment in innovation, combined with in-depth application know-how, targeted acquisitions, and customer intimacy. Turning to other markets, sales to industrial capital equipment saw a decline year-over-year. This market is mainly served by our precision manufacturing business, which was affected by the impact of trade disruptions and customer demand, particularly in China. However, revenue has now stabilized at this lower level, and bookings are rising at double-digit pace, both year-over-year and sequentially, as customer inventories are mostly depleted and visibility improves. Coupled with the new design wins more than doubling year-over-year for the second consecutive quarter, this positions us well for sequential revenue growth through the second half of 2025 and beyond. We're gaining traction in additive manufacturing for medical and aerospace applications and applications supporting AI investments like advanced packaging and on-device AI computing, which demand extreme precision, throughput, and miniaturization, areas where Novanta's scan head subsystems excel. Also, as supply chains regionalize, we see growth opportunities in new markets such as India, where we are expanding our commercial presence and have had recent success winning new customers. Next, in advanced semiconductor applications, in the near term, this market continues to show mixed signals, but appears to be in the early phases of an upcycle, albeit at a slow pace. Our short-cycled sales are still strong on the back of capacity build-out for new data centers and other AI-related infrastructure. As for our new content in deep UV and EUV applications, we're shipping small amounts of early units, and we will be ramping up as our customer ramps in the marketplace. We're designed in on an exclusive basis with this new content, and we expect significant sales growth over the next few years. Finally, speaking to life science equipment markets, which is mainly served by our precision medicine business, this area saw a year-over-year decline caused by weakened market dynamics, including further disruptions at the U.S. NIH and FDA, big biotech funding cutbacks in pharma CapEx, and trade disruptions. Due to these market disruptions, we're starting to see customers accelerate a replacement cycle away from barcoding and older instruments as they focus their new product development on more advanced technologies such as RFID and machine vision. Over the last two years, we've been aggressively shifting our product offering into these new technologies. For RFID, we feel that with the Keonn acquisition, we've successfully positioned ourselves at the leading edge of new RFID solutions offerings. As for machine vision, we're happy to announce that in the second quarter, we entered into a new commercial partnership with a global leader in machine vision technologies to sell their embedded machine vision to OEM customers in the life sciences sectors. This partnership leverages our partner's leading machine vision technology, combined with Novanta's deep domain and application knowledge of medical and life science applications, including our ability to provide tailored support to our OEM customers. While the recent decline in revenue has been more than expected, we were encouraged to see our precision medicine business grow double-digit sequentially in the second quarter, largely because of our accelerated transition to these more advanced technologies. Based on this, we believe the revenue will stabilize over the next several quarters and expect it to grow sequentially the remainder of this year. We continue to believe in the long-term secular opportunities in the life science equipment market. Early detection of root causes of disease will continue to be a big driver of productivity in the healthcare industry, and we will continue to execute our long-term growth playbook in this market, albeit that in the near term, we're managing the profit flow-through of this business and shifting our capital allocation plans. Now I'll provide an update on our acquisition activities. The Keonn integration is on track, and the business performance is already beating our initial expectations. Our short time with this team has proven their leading expertise in software development and RFID technology solutions, and they also have succeeded at winning a large new customer, which we believe will offer excellent near-term growth for the business, helping the second half sales outlook of 2025 with continued double-digit growth in 2026. Looking beyond Keonn, acquisitions remain a top priority for our team to continue to evolve our portfolio towards high-growth medical, more recurring consumable-based, and more embedded software and intelligent subsystems. We continue to have a large and exciting pipeline of targets. Valuation levels are more attractive, and we believe that the near-term macroeconomic environment is an added catalyst to increase actionability. Our balance sheet is well positioned for additional transactions while maintaining our historical discipline in both cash returns and financial leverage. You should expect us to lean in hard to pursue additional transactions in the second half of 2025. To conclude, I'm very pleased with our second quarter performance. We met or exceeded our expectations for sales, margins, and profit, driven by double-digit growth in our advanced surgery and robotics automation businesses, underscoring our strategic focus on high-growth markets and the diversity of our portfolio. Our new product launches continue to ramp, and we remain confident in achieving our goal of $50 million incremental new product sales. We also had 10% year-over-year growth in bookings, which, combined with the new product ramps, sets us up for steadily increasing sequential growth in 2025. We're also well positioned for growth in 2026 based on multiple significant new design wins in high-growth markets such as minimally invasive surgery and also physical AI applications like warehouse robotics. The Keonn acquisition is off to a great start, and we have an additional large pipeline of exciting actionable acquisition targets. We remain focused on our top three priorities for Novanta in 2025. First, ramp all our planned new products and achieve the $50 million growth from new products this year. Second, deliver strong profit margin and cash flow performance by driving NGS deep into our culture and operations and successfully execute on our tariff response playbook. Third, acquire additional companies that fit our strategy at attractive returns and in a manner that evolves our portfolio to secular growing and resilient markets and business models. With that, I will turn the call over to Robert to provide more details on our operations and financials performance. Robert? Thank you, Matthijs. Our second quarter 2025 non-GAAP adjusted gross profit was $111 million, or a 46.1% adjusted gross margin, compared to $110 million, or a 46.6% adjusted gross margin in the second quarter of 2024. Adjusted gross margins were down year-over-year, but flat sequentially and in line with our expectations, despite the increased cost of tariffs. For the second quarter, R&D expenses were $25 million, or approximately 10% of sales. Second quarter SG&A expenses, excluding ERP design costs, were $45 million, or approximately 19% of sales. The ERP design costs of the quarter were approximately $1 million. Adjusted EBITDA was $52 million in the second quarter, or 22% adjusted EBITDA margin, demonstrating growth of 2% year-over-year. On the tax front, our non-GAAP tax rate for the second quarter of 2025 was 21% versus 20% in the prior year. Our tax rate increased year-over-year, mainly due to changes in jurisdictional mix of pre-tax income. Our non-GAAP adjusted earnings per share was $0.76 in the second quarter, up 4% versus the prior year. Operating cash flow for the second quarter of 2025 was $15 million, compared to $41 million in the second quarter of 2024. The year-over-year decrease in operating cash flow was primarily driven by the timing of tax payments, an increase in inventory purchases to mitigate the global trade dynamics, which were at their peak in the second quarter, and from the acquisition of Keonn. We expect cash flow conversion rates to return closer to historical averages in the third quarter. We ended the second quarter with gross debt of $465 million, with a gross leverage ratio of 2.2 x, and our net debt was $355 million, giving us a net leverage ratio of approximately 1.7 x. In the quarter, we acquired Keonn for approximately $75 million. As a reminder, Keonn combines proprietary RFID hardware with AI-enhanced cloud-based software to offer real-time inventory and asset management, filling a crucial software integration gap for better penetration into the medical markets, including hospitals. We also amended our credit facility in the final week of June, increasing its size to approximately $1 billion and adding a $350 million accordion feature, giving us nearly $1.4 million of borrowing capacity over the next five years. This new pro-rated bank facility gives us borrowing capacity to pursue our acquisition strategy while maintaining the debt leverage discipline we have practiced over the last decade. Now, I'll share some additional performance metrics and some details on our operating segments. For the second quarter, Novanta had a 10% growth year-over-year in bookings and 20% growth sequentially, and a book-to-bill ratio of 1.02, reflecting strengthening backlog and a strengthening outlook. We saw a continued strong pace of bookings in both our segments, demonstrating not only stabilization of demand but also increased demand outlook for 2026 and the continued strong momentum of new product launches. In the second quarter, medical market sales represented 54% of total Novanta sales, and advanced industrial markets represented 46% of total sales. New product sales grew by more than 50% year-over-year, and our vitality index climbed to 21% of total sales. We are seeing growth in new product sales across all businesses, but especially the medical solutions segment. Through the first half of the year, we launched over a dozen new products, mainly focused on high growth end markets in advanced surgery and robotics and automation. Also in the quarter, as we mentioned, we saw excellent design win activity, with the company-wide design wins growing over 150% year-over-year. The second quarter, automation enabling technology segment revenue grew by 4% year-over-year, beating expectations and driven by continued strength in the robotics and automation business unit, which was up nearly 16% year-over-year. The book-to-bill in this segment was 1.05, and bookings were up 8% year-over-year and 17% sequentially, giving us improving customer visibility. Adjusted growth margins in this segment were approximately 49%, up 40 basis points year-over-year, driven by favorable mix but partially offset by the increase in tariff costs. Both new product revenue and customer design wins doubled year-over-year on the back of both our innovation and stronger commercial execution by our teams. In addition, the vitality index was in the high teens percent of sales, up significantly versus the prior year. Moving on to medical solutions, revenue in this segment was roughly flat year-over-year. This segment saw a book-to-bill of one in the second quarter, and bookings were up 13% year-over-year, but up 26% sequentially on the back of record new product launches. New product sales in this segment grew by over 30% year-over-year, and the vitality index in this segment was over 25% of sales in the second quarter. Our advanced surgery business experienced 17% growth year-over-year, driven by both strong patient procedural growth rates in healthcare on a global basis and from the launch of our second-generation smoke evacuating insufflators, which have received overwhelming market acceptance and adoption. These growth dynamics are expected to continue for the remainder of the year and well into 2026. Conversely, our precision medicine business, which serves the life science and multi-omics markets, experienced a 13% decline in sales year-over-year. However, sequentially, the business grew 10% and is expected to continue to improve sequentially in subsequent quarters. Adjusted gross margins in this segment were approximately 44% in the quarter, flat sequentially and in line with the expectations, but slightly higher tariff costs, which we expect to mitigate further in the third quarter. Finally, moving to guidance, let me give you an update on our tariff response plan. Speaking first, the impact of tariffs on our supply chain, our cost mitigations are largely on track, and we continue to work on efforts to accelerate our plans. With some of the recently announced trade deals at higher than expected permanent tariff rates, we are seeing approximately a $4 million net impact from tariffs year to date on our cost of sales. However, we continue to make strong progress with both tariff mitigation strategies and cost mitigation strategies to further reduce the impact in the second half. Next, to address the matter of impacts on tariffs between the U.S. and China, while tariffs have remained paused between the two countries, there is optimism a trade agreement being reached quickly. Our customers in China continue to be cautious with placing committed purchase orders on goods from our U.S. factories. As such, we are working with them on accelerating our plans to shift production to non-tariff regions and are exploring further short-term mitigation strategies to minimize the risk of ordering products from us. While Chinese customers ordering product from our U.S. factory has been muted, design win activities with our Chinese customers have accelerated, which we believe signals to us that our Chinese customers have confidence that we have the right tariff mitigation strategies to reduce their costs and risks, and that they are excited about our new product innovation and what it can do for them in their markets. In addition, demand for our products manufactured in China, which is our in China for China strategy, accelerated in the quarter, which drove our total China sales up 15% year-over-year in the quarter. Finally, due to the fluid and ever-changing nature of the global trade environment and the resulting implications on end market demand at the end of June, we launched our cost reduction plans that we had previously announced, including changes that support the regional manufacturing strategy. Over the long run, we expect these actions to structurally improve our costs by simplifying our operating model, allowing further expansion of our gross margins while permanently minimizing the disruptions from tariffs on our products and for our customers. The total restructuring charges related to this program are expected to be in the $20 million - $25 million range, with the bulk of the savings run rating in the fourth quarter of 2025 and into 2026. Novanta is committed to deliver sequential revenue and profit growth driven by our innovation pipeline, robust customer demand in secular growth markets, and operational discipline, including our cost reduction efforts and the regional manufacturing strategy. Despite the rapid changes in tariffs and trade agreements, we believe we have navigated this well and have quickly adapted to the environment. After several years of investing heavily in R&D to deliver breakthrough innovations to our customers, the results of those efforts are materializing in our financials, in our design wins, and in our new product revenue. With a stabilizing demand environment, as evident by our bookings growth, we believe we are well positioned to accelerate our organic growth initiatives further when the macroeconomic tailwinds improve. While trade dynamics could further disrupt our outlook, increased visibility from our customers is giving us confidence to reissue full-year guidance, albeit with some caution. As such, we now expect full-year 2025 GAAP revenue to be approximately $970 million - $985 million, which represents overall revenue growth of 2% - 4%. For adjusted gross margins, we expect to achieve approximately 46%. This outlook includes the cumulative impact of expected tariff costs and the associated temporary redundancy in costs from our regional manufacturing strategy. Excluding those extra costs, we would be on track to achieving our goal of 100 basis points of gross margin expansion this year. This resilient margin performance is thanks to the Novanta Growth System, the business system that is allowing us to maintain our financial commitments despite the cost headwinds. We expect R&D and SG&A expenses for the full year to be approximately 28% of sales, or between $274 million and $278 million. This guidance includes expected costs associated with the design and planning phase of a standard ERP system, which is scheduled for a phased deployment starting in 2026 and taking place over multiple years, further supporting our footprint consolidation and our regional manufacturing strategy. Besides improved scalability and resiliency benefits, this also supports our gross margin expansion plans and operating expense reduction plans. Depreciation expense should be approximately $16 million for the full year. Stock compensation expense should be approximately $37 million for the full year, which includes the change in incentive compensation plans, which we made for all our incentive-based employees, aligning them tightly with our strategy, driving strong employment engagement and aggressively driving shareholder value, while also reducing near-term cash needs. For adjusted EBITDA and for the full year of 2025, we expect to be $225 million - $230 million, or approximately a 23% EBITDA margin. This represents year-over-year growth of 7% -1 0%. Interest expense is expected to be roughly $23 million for the full year of 2025, excluding any material changes in debt balances. We expect our non-GAAP tax rate to be around 22% for the full year. We are still analyzing the effects of the new corporate tax law changes, and as such, have not incorporated these changes fully into our full-year rate. Diluted weighted average shares outstanding will be between 36 million and 37 million shares. For the full year of 2025, our adjusted diluted earnings per share we now expect to be approximately $3.22 and $3.36, representing growth of 5% - 9%. Finally, we expect strong cash flow for the full year from both lower cash taxes in the second half, as well as better inventory management and stronger profit. Moving to the third quarter of 2025, we expect GAAP revenue in the range of $244 million - $247 million, which represents a year-over-year change in reported revenue growth of flat to up 1% and sequential growth of 1% - 2%. At the segment level in the third quarter, we expect the Automation Enabling Technology segment to range flat to low single-digit decline year-over-year, caused largely by lower exports from U.S. factories to Chinese customers, something we expect to better mitigate in the fourth quarter. We expect this segment to grow sequentially 1% - 2%. Our Medical Solutions segment is expected to demonstrate mid-single-digit growth year-over-year and up sequentially approximately 3% from continued strength in advanced surgery at growth rates comparable to those demonstrated in the second quarter and from a sequentially improving precision medicine business. Moving on to adjusted gross margin for the third quarter, we expect to be at nearly 46%. This outlook includes the cumulative impact of expected announced tariffs, as well as some near-term redundancy in costs from our regional manufacturing strategy, which we expect to overcome in the fourth quarter. We expect R&D and SG&A expenses in the third quarter to be approximately $68 million - $69 million. Similar to our full-year guidance, we have excluded expected costs associated with the design and planning phase of our standard ERP system. Depreciation expense, which is approximately $4 million in the second quarter, will be similar in the third quarter. Stock compensation expense was $7.5 million in the second quarter; it will be nearly $11 million in the third quarter. This increase in quarterly stock compensation expense is driven by both the retention and incentive equity awards associated with the Keonn transaction, as well as the in-quarter impact with the change of incentive compensation plans, which we discussed earlier. For adjusted EBITDA for the third quarter, we expect a range of $57 million - $60 million. Interest expense, which was $6 million in the second quarter, will be similar in the third quarter, and we expect our non-GAAP tax rate to be around 22%. For adjusted earnings per share, we expect a range of $0.78 to $0.85 for the third quarter. Finally, we expect third quarter cash flows to rebound versus the second quarter and return to a cash conversion rate closer to the historical averages we have demonstrated. This updated outlook considers our latest view of the end markets, the continued successes of our new product launches, foreign exchange rates based on the second quarter, and the signed tariff agreements, trade agreements between the U.S. and its trading partners as of July month end. However, in this environment, the dynamics of both trade and foreign exchange, as well as government-sponsored funding and regulatory disruptions, are ever-evolving and therefore subject to change. We continue to have confidence in our ability to navigate these dynamics and adapt quickly. Finally, with improvements to both our core business and long-term visibility to customer demand, along with a strong balance sheet and strong credit facility, we are well positioned to accelerate our acquisition pipeline with more meaningful and impactful acquisitions. Given our current acquisition pipeline, we feel confident in executing a transaction by year end. In summary, we are confident in the fundamentals of our business, the long-term strategy, and our business model remains intact. We are excited about our new customer wins and the success of new product launches. We continue to make strong progress in high-growth markets, particularly in medical markets and physical AI robotics markets. As a company, we remain focused on controlling what we can control and executing with excellence on our strategy and top priorities, no matter what the market environment brings. This concludes our prepared remarks. We'll now open the call up for questions. We will now begin the question and answer session. To ask a question, you may press star, then one on your touch-tone phone. If you are using a speaker phone, please pick up your handset before pressing the keys. To withdraw your question, please press star, then two. Our first question will come from Lee Jagoda of CJS Securities. Please go ahead. Hey, good morning, guys. Morning, Lee. I guess, Robert, just to start, can you break down your revenue guidance? You can use the midpoint, I guess, in terms of growth from Keonn, the impact of FX, and then the true organic growth underlying? it for the second half or for the full year? Full year or second half, either one or both. Okay. For the full year, you know, the reported on an organic basis, it will likely be down 1% to up 1%, somewhere in that range. What's the FX implied impact or benefit? The same FX impact that we have in the second quarter, we just carried that forward for the full year. Got it. The delta is really the Keonn acquisition. Gotcha. Perfect. Which is, to be fair, has done significantly better than expected. Got it. I was hearing all the color around the new products over the next several years was really good and interesting earlier. Given you kind of have pretty good visibility about your product roadmap, what do you think are the biggest drivers of organic growth in 2026 in terms of the new products independent of whatever the market's going to do? Yeah, hi, Lee. This is Matthijs. Basically, continuation of the advanced surgery product ramps, right? We are basically having the first year of ramps this year, and that will continue to expand. That's one. Secondly, the physical AI, basically the AI-enabled robotics market, warehouse automation. You heard us comment about a $50 million contract we've won there, where we see rapid deployment of robotics in advanced warehouse automation applications. These robots need a sense of touch and a sense of fast and safe movement, and we have unique capabilities to help in that application. Third, we see, let's say, related applications. Humanoids still will be small, but what we commented on is that the overarching industrial physical AI applications will double in 2026 versus 2025, and then again, double again, be it from a small base, but that kind of tells you that we're growing. Finally, we are seeing, let's say, very, very strong design wins that will start to ramp. For at the company level, 150% year-over-year. Now, they won't all ramp in 2026 fully, but they will start to ramp, and that's a visibility we have. Again, a wide variety of applications. I commented on, let's say, additive manufacturing driven by aerospace and medical. What you see is that, of course, with the whole tariff and trade environment, people want to produce locally, and actually, additive manufacturing is a very good way to do that. We're seeing some significant traction there, and we've won some business, some significant business there. Also, what I would call advanced material processing, applications that are actually supporting some of the on-device AI investments in advanced packaging related to advanced AI or related markets. Those are a few areas that we see, we're excited about, that we commented on, and that we see growing, you know, despite whatever the environment will bring. It shows you that we're staying laser-focused on these secular growth markets, no matter the environment. With the innovation and customer intimacy, we're very encouraged by everything that is happening there. Within life sciences. One thing I'd add there. Yeah. Sorry. Yeah, go ahead. Sorry, Lee. Go ahead. No, go ahead. The only thing I was going to add is that the advanced surgery business should continue to demonstrate the same level of growth, which is kind of the mid-teens type growth as we get into next year. Our robotics and automation business should continue to participate as a consequence of new design wins and new product introductions, somewhere in that 10% type of range. If you just factor in that you're not going to see the same level of declines in our industrial or precision manufacturing business, nor the precision medicine business, that would give you a pretty good indicator of what 2026 is going to look like. That's sort of where I was going to go next. In industrial and precision medicine, it sounds like you're seeing certainly some signs of improvement in the industrial and maybe, you know, at a minimum bouncing along the bottom in life sciences. I guess have we seen the low point for the year in your mind in those two areas? Sitting here today, are we looking at sort of a flattish 2026 for those end markets, or could they still decline further? Based on what we see today, and again, you know, you never know with, of course, the trade changes, but based on what we see today, based on the bookings and the customer outlook, which is actually improving, right? Customer inventories on the industrial side have been depleted, and we see 2026 backlog actually building on the industrial side. We see the business sequentially improving in the second half of the year. Based on that, yeah, we see that business has reached its bottom and then sequentially improving from here. The precision medicine also, we commented that that's more of a technology shift in addition to market dynamics. The market dynamics we don't necessarily see improving in the near term, but we do see the technology shift based on the machine vision as well as the RFID transitions that we're making. We see that having a sequential improving effect on the business, and therefore we see that business sequentially improving as well. Yes. The outlook for life science is a little bit unclear, but what we do is we just focus on what we can control, which is those new technologies as well as we're aggressively managing profit flow-through as well as capital allocation, of course, to these areas that have really strong tailwinds like physical AI advanced surgery. Perfect. I'll hop back in queue. Thanks. Thanks, Lee. The next question comes from Brian Drab of William Blair. Please go ahead. Hi, thanks. First, Robert, you touched on China and tariffs. Did you say specifically status? Did you talk about it in the same context about the $35 million that was held up? Is it still $35 million at risk for the year? Yeah, the $35 million is factored into our guidance right now. We haven't assumed that we're going to recover that yet. That's where we issued the guidance that I made a comment around with some caution. We're not seeing the order behavior yet from our customers in the second quarter. As we enter the month of August, the same holds true. That's largely just because of the uncertainty with how those tariffs would unfold. When you're ordering product from a U.S. factory with a 90-day lead time, they can get themselves stuck in a position on a non-cancelable purchase order where they'll be importing at an unknown expense to them because they don't know what the tariff cost is going to be. That being said, what I see as an offset is the local, first and foremost, we're growing in China for China. That strategy, which represents 50% of our sales into overall exposure of China sales, is growing. As a consequence, we saw total China sales up 15% year-over-year. Despite missing that, we still got some impressive growth happening. Second, the design win activities with our Chinese customers did accelerate. We are seeing signals from them to design our technology into new product, which effectively you would not do if you thought the situation was going to be permanent. Effectively, our strategy of how we're going to mitigate tariffs is being well received by our customers, and they're being as patient as they can until we get those fully implemented. Could we get that turned around by the fourth quarter? Yes, it's possible. Not third quarter, but definitely by the fourth quarter. It's possible to get that rectified and start clawing back some of that revenue, but we haven't factored that in at this time until we have better visibility around the execution of that plan. Yeah, it's driven, Brian, by the transfer of manufacturing, right? Our customers, we shared those plans. They're confident in our plans. That's why the design wins are continuing. The actual transfers are starting to happen in the fourth quarter, which is really the mitigation, right? It really depends how quickly you can rectify and ramp from there. Structurally, we're addressing it. It's really a timing issue that we're working through. Understood. Are those design wins in China, medical, industrial, robotic surgery, did you say? Mostly industrial and robotics. Our robotics and automation business, of course, Matthijs went into some details around that. There are a lot of new products launched around that, but we're also seeing nice design win activities in our precision manufacturing business. Okay. Can you say if any of those humanoids? All our, we've mentioned 10 humanoids for vendors or customers that we have. Those are, we're very specific in the language saying that they're U.S. and European exposure. I would say the bulk of our humanoid exposure today is in the U.S. and European markets. We'd be reluctant to say that, you know, there's anything in China at this point in junction. Yeah, some, but not a lot, I would just say. We're not banking on that, but there are other precision robotics markets, both surgical as well as kind of adjacent to warehouse automation, that are getting traction and where we feel we got a very good offering. Okay. Thanks. Just one more for now, I guess. Can you talk a little bit more about maybe the specific use case within the warehouse for the warehouse robotics win and what type of technology are you winning with? Like, is it force torque or servo drives, the haptic? I've got one more piece to this question. Could this be much bigger than $50 million down the road? Yeah, thanks, Brian. Let me kind of try to parse that out. You're welcome. First and foremost, what you see is that vision alone will not do the trick in these really advanced warehouse automation markets where you're going to almost process goods faster than humans. You have to mimic humans in terms of touch. It's proven by one of the leader players that the touch is actually essential. The fast and safe reaction to what you're sensing, and then turning that into motion and doing that safely, is actually very complicated if you do that in a small form factor at the edge, meaning at the end of the factor where the action happens. Novanta has unique capabilities to do this in a small form factor very precisely and reliably to the extent that the tremendous demands on these applications, where you basically cannot drop a package for, you know, maybe you can drop a package like once in 24 hours, which means extreme accuracy. That's what we bring to the table. That then provides that high conviction of these warehouse automation players to start deploying this because now it's actually possible to replace humans. That is what that is. There is a massive amount of capital that is being deployed. That's all public. What we like about it is, of course, the use case is there. It's proven in the warehouses. The capital is there. It will be a multi-year deployment cycle. We've commented on, and you know us, we're kind of conservative. We only will quote things that we have won and that we've contract signed. That's the $50 million. I do believe, and we do believe that down the line, if you combine all these physical AI applications and you look at the served available market for us, based on conservative estimates, that's about a $1 billion market in 2030. We are aiming, of course, to get a decent chunk of that. We think it's a sizable opportunity down the line. We're allocating and deploying resources aggressively to both ramp and continue our new product innovations, which we feel are leading in the industry. That is force or sensing, that is servo drives. It's also including encoders, let's say, all in a subsystem package that works in the different use cases for these OEM players. Whether it's warehouse automation or humanoids or related applications, these robots don't necessarily have to stand on two feet. That's maybe the last thing I will say. You see a lot of application-specific related applications where you see robots on wheels or you see them fixed in a location, but doing very similar smart tasks. Hopefully that answers the question. Yeah, that was really interesting. Congratulations on the warehouse win and all the other wins you announced this quarter. Thanks. Thanks. The next question comes from Rob Mason of Baird. Please go ahead. Hey, good morning. Maybe just to follow on your last response, Matthijs, when you were talking about the entire package of, you know, your offering into this market, force torque and servo drives and encoders, was that the case for this particular warehouse automation contract, or was that just force torque because you mainly were referencing sensing? It's the sensing and the reaction. It has both the servo drives as well as the sensing capabilities. Again, we're commenting on this one player, but we've won multiple warehouse automation design wins that are a bit smaller than this, where we use basically the whole gamut of the different capabilities. It depends a little bit on the player, how much of one versus the other is being used. I would say holistically, it's true that both in warehouse automation and humanoids, as well as surgical robotics, these capabilities are getting more important going forward. The sense of haptic feedback in surgical robotics is a key capability. It's basically the same capability that gives the robot in the warehouse a sense of touch, as well as the humanoid, right? In all these applications as well, the low latency, meaning fast response safely, so humans can work side by side with these robots safely. Embedded safety is not trivial. We do that embedded into our servo drives, which is unique at a very small form factor, super precise, very high power density, which means that small form factor, yes, very powerful. All these things combined make us uniquely qualified for these applications. The short answer is both capabilities are included in these applications. Right. I see. As you've talked about the ramp in these products in 2026 and 2027, are you needing to add additional capacity? Do you have current capacity to serve this? Yeah. No, we do. On the other hand, this is, and I'm glad you asked this question, it's a unique example of how the Novanta Growth System can really help to increase capacity very efficiently. We just completed a Kaizen with over 20 people, just cutting lead times down by a factor of three, increasing capacity by a factor of four to five without adding major capacity. Down the line, we see this ramp growing beyond that. Yes, we will have to automate and, you know, eat our own dog food, so to speak, right? Put automation in our lines to kind of get through these really high volumes. The answer is yes. We're using the Novanta Growth System to do this efficiently and reliably. I see. Maybe just last question. One of the end markets you touched on, you said was mixed, was around the semiconductor electronics area. I'm just curious. We have seen, really over the past year, I guess, some pushes to the right in that industry. How does that factor into your second half guide around new products, whether that gets into the lithography space you're talking about? I'm just curious if you've had to shuffle some of the plans again around that. I would say that any sort of risk associated with those applications has been factored into our second half guidance, as well as the before-mentioned China situation where we are not anticipating that revenue in our guidance to come back. Although that's looking more and more possible, particularly as we start to look at Q4. We are shipping units into those applications in the fourth quarter. There are some units going out. They're not at the volumes that we were hoping for before, but we feel very good because we're still designed in on a sole source basis into those applications. We've doubled the content that we've had in from a per-unit basis than we've had in prior periods, and we have some backward compatibility with some of our technology. We feel very good that we have the right technology and the right application positioned on a sole source basis that's positioned for growth. We're just waiting, anticipating as that market works through some dynamics to allow those shipments to really ramp up to the volumes that we're hoping for and that have been communicated. I see. Very good. Thank you. Yep, thanks, Rob. This concludes our question and answer session. I would like to turn the conference back over to Mr. Matthijs Glastra for any closing remarks. Thank you, operator, and thank you, everyone, for your questions. In closing, as always, I would like to thank our customers, our shareholders, and especially our dedicated employees for their ongoing support. We appreciate your interest in the company and your participation in today's call. I look forward to joining all of you soon at our third quarter 2025 earnings call. Thank you very much. This call is now with.